Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

2005621 citationsJournal Articlebronze Open Access

Authors

Jan P. van Meerbeeck · University Hospital Heidelberg

Rabab Gaafar · European Organisation for Research and Treatment of Cancer

Christian Manegold · Erasmus MC

Rob J. van Klaveren · European Organisation for Research and Treatment of Cancer

Eric A. Van Marck · University Hospital Heidelberg

Mark Vincent · European Organisation for Research and Treatment of Cancer

Catherine Legrand

Abstract

A combination of raltitrexed and cisplatin improves overall survival compared with cisplatin alone. This study confirms that a combination of cisplatin and an antifolate is superior to cisplatin alone in patients with MPM, without harmful effect on HRQOL.

Topics & Keywords

Occupational and environmental lung diseases Pleural and Pulmonary Diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 28, pp. 6881-6889

DOI: 10.1200/jco.20005.14.589

Field-Weighted Citation Impact: 30.31